Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
about
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsStent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysisHigh residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistanceEffects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Drug-Eluting Stent Implantation: A Nationwide Cohort StudyEfficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled TrialsThe 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trialAntiplatelet and anticoagulant drugs in interventional radiology.Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity.Characterization of platelet dysfunction after trauma.Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review.Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry.Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity.Platelet dysfunction and inhibition of multiple electrode platelet aggregometry caused by penicillinSerotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.Platelet aggregation and clot formation in comatose survivors of cardiac arrest treated with induced hypothermia and dual platelet inhibition with aspirin and ticagrelor; a prospective observational studyEffects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery diseaseIndividualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.Different influences of hematocrit on the results of two Point-Of-Care platelet function tests, the VerifyNow assay and multiple electrode platelet aggregometryCYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis.Platelet function tests: a comparative review.Point of care platelet activity measurement in primary PCI [PINPOINT-PPCI]: a protocol paper.Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.Antiplatelet resistance and the role of associated variables in stable patients treated with stenting.Effect of gender difference on platelet reactivity.Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.Phenotyping patient-derived cells for translational studies in cardiovascular disease.Variability of platelet aggregation in patients with clopidogrel treatment and hip fracture: A retrospective case-control study on 112 patientsA Study of Platelet Inhibition, Using a 'Point of Care' Platelet Function Test, following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction [PINPOINT-PPCI].Do Clopidogrel Nonresponders Have an Increased Risk of Adverse Events during Supra-Aortal Angioplasty and Stenting?Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept studyIncidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.Assessment of platelet function in patients with stroke using multiple electrode platelet aggregometry: a prospective observational study.Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial.Altered clot microstructure detected in obstructive sleep apnoea hypopnoea syndrome.Whole blood impedance aggregometry as a biomarker for the diagnosis and prognosis of severe sepsis.
P2860
Q26775125-F3D81152-5A12-4EEA-8EBA-A3070995365FQ26785321-6509E07A-A21A-4F6C-8352-64EC47A306ADQ26824694-A45E2E5F-4C0D-4E8A-8140-4AFFC47C90E7Q26824850-E008BB49-7DC5-4420-AD7B-3D67453CDB39Q28547539-F4C7DF10-7F52-443F-BEF1-CC035A431804Q28548148-D3579F28-62B7-4232-8BA0-1A1B34B6349EQ30513934-594A2F39-E5B5-4331-B776-96509946DAD1Q33395898-B6B0E625-7270-4AEB-AC0D-0118BA3329C0Q33399119-F7ADD8A2-344D-4E03-857D-F66AEBDBC654Q33402029-E92F4B92-77EF-494E-B5AA-0586B0378A31Q33440890-87DA041A-8485-4DBD-A4DB-2F074B63E0ACQ33804996-A06917CF-ADD8-46DC-B0A3-41F11D37AEC7Q33881728-B8EFC794-FDFA-47CD-8721-F7AEE4392FC7Q33982372-B5297B6D-B351-4846-819E-DCBF9BD5CDF3Q34014099-1668E04F-C5F5-4DB9-95F5-9ACA168E16CEQ34043684-353362C4-38F7-466B-BB06-63D38AD60EBCQ34182816-61163576-FEBB-47AD-8ACC-EBAC758B8C20Q34325757-890A27C7-837F-4B3B-9BE5-A77886F1780AQ34352152-40D4C76A-A0C5-4D51-AA04-8F6C4556A159Q34439089-037888B5-3871-4C7E-A594-15882B248B99Q34576640-176011EC-C78F-4F56-82C1-957C28260BA5Q34649009-28A3EE5F-01A2-4F96-A27D-F77BE7B322F2Q34763870-06A56F97-8DEC-4E80-828C-12560F2B44DDQ35121464-FC42F363-A51F-47CC-94C2-28E3AB7222E8Q35141218-E33B15B1-6519-478A-A710-4C51C0C79C59Q35141772-DBA9E933-3C99-47F4-B2DB-41B89BD5E48EQ35214494-91630DA5-5923-446D-9BBB-56E59249ABBCQ35473568-9B4ADE70-964E-4651-83FD-2CFA911A2D65Q35658513-2933D126-EB62-4430-A7B6-9908123BC4F5Q35686793-F2930C4A-9984-426F-AAE6-5108319F6652Q35691358-08F5D571-F7BD-42C4-82D8-9A2EA7E70089Q35870016-E21EFB25-F925-4C99-807C-CD003D8AEBDEQ35897821-BA01B601-E73F-4E60-A927-BAFD151FE29DQ36020320-BD90B099-8256-4317-A037-2654CB7D11E9Q36054209-1B2796DD-071D-4366-8E76-57595F30BE23Q36216424-FFE6692E-2FB6-4106-B095-C6768491E865Q36219096-E48D7081-27A5-42D2-996C-1846BFC6C358Q36688145-114077D0-F47B-4740-A4CA-7DD5F4945FA7Q36903788-4F8B63BE-4BC5-4FA5-9376-20500A6C3B50Q36928258-F7978099-791C-4F69-B5DF-D37C65AE6B33
P2860
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Platelet reactivity after clop ...... drug-eluting stent thrombosis.
@en
Platelet reactivity after clop ...... drug-eluting stent thrombosis.
@nl
type
label
Platelet reactivity after clop ...... drug-eluting stent thrombosis.
@en
Platelet reactivity after clop ...... drug-eluting stent thrombosis.
@nl
prefLabel
Platelet reactivity after clop ...... drug-eluting stent thrombosis.
@en
Platelet reactivity after clop ...... drug-eluting stent thrombosis.
@nl
P2093
P50
P1476
Platelet reactivity after clop ...... drug-eluting stent thrombosis.
@en
P2093
Dirk Sibbing
Siegmund Braun
Tanja Morath
Wolfgang Vogt
P304
P356
10.1016/J.JACC.2008.11.030
P407
P577
2009-03-01T00:00:00Z